Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract - Is there evidence for discordant biology?

Laura Maria Krabbe, Yair Lotan, Aditya Bagrodia, Bishoy A. Gayed, Oussama M. Darwish, Ramy F. Youssef, Christian Bolenz, Arthur I Sagalowsky, Ganesh Raj, Shahrokh F. Shariat, Payal Kapur, Vitaly Margulis

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Purpose Upper tract urothelial carcinoma is rare and less well studied than bladder cancer. It remains questionable if findings in bladder cancer can safely be extrapolated to upper tract urothelial carcinoma. We prospectively evaluate molecular profiles of upper tract urothelial carcinoma and bladder cancer using a cell cycle biomarker panel. Materials and Methods Immunohistochemical staining for p21, p27, p53, cyclin E and Ki-67 was prospectively performed for 96 patients with upper tract urothelial carcinoma and 159 patients with bladder cancer with nonmetastatic high grade urothelial carcinoma treated with extirpative surgery. Data were compared between the groups according to pathological stage. Primary outcome was assessment of differences in marker expression. Secondary outcome was difference in survival according to marker status. Results During a median followup of 22.0 months 31.2% of patients with upper tract urothelial carcinoma and 28.3% of patients with bladder cancer had disease recurrence, and 20.8% and 27.7% died of upper tract urothelial carcinoma and bladder cancer, respectively. The number of altered markers was not significantly different between the study groups. Overall 34 patients (35.4%) with upper tract urothelial carcinoma and 62 (39.0%) with bladder cancer had an unfavorable marker score (more than 2 markers altered). There were no significant differences between upper tract urothelial carcinoma and bladder cancer in the alteration status of markers, the number of altered markers and biomarker score when substratified by pathological stage. There were no significant differences in survival outcomes between patients with upper tract urothelial carcinoma and those with bladder cancer according to the number of altered markers and biomarker score. Conclusions Our results demonstrate the molecular similarity of upper tract urothelial carcinoma and bladder cancer in terms of cell cycle and proliferative tissue markers. These findings have important implications and support the further extrapolation of treatment paradigms established in bladder cancer to upper tract urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)926-931
Number of pages6
JournalJournal of Urology
Volume191
Issue number4
DOIs
StatePublished - Apr 2014

Keywords

  • biological markers
  • carcinoma
  • transitional cell
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract - Is there evidence for discordant biology?'. Together they form a unique fingerprint.

  • Cite this